CureVac is pioneering the therapeutic application of messenger RNA (mRNA), opening up an entirely novel class of drugs.
The Company's approach is based on the in-house discovery that when modified, the direct application of mRNA via injection can lead to the expression of functional proteins.

NEWS & EVENTS

2009-11-02
CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer pfeil

CureVac beginnt Phase-IIa-Studie mit mRNA-Vakzin zur Behandlung von Prostatakrebs pfeil

DOWNLOADS

CureVac at a glance

Company Profile